Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (359)	5/3/1999 9:28:00 AM
From: LLCF	Respond to of 3158

Yes, saw the CNTO... they also mention "Munching" in general and list munchors as: Abbott, Bristol, AHP, AMGN, CHIR, Immunex, Genentech. Also, was this for Rick: Biotech Ego's Biotech has been through less consolidatio that other industries in recent years as it's been tough to find combinations that boost profit of the acquirer since most biotech companies are unprofitable. And egos have also gotten in the way of potential deals because few biotech chief executives have been willing to step down, investment bankers have said. Attitudes have changed i the past few years as biotech CEO's have grown weary of repeatedly seeking new financing to keep money-losing companies running until they become profitable. Profitable biotechs are under pressure as well from investors to develop new products, while keeping sales and profits growing. "There are very few companies that are maturing rising stars that would continue on their own for very long, said Virn Mehta, and analyst with Mehta Partners. They are facing heavy investments while trying to balance investor demand for predictable and rising earnings to maintain their high multiples. DAK